AbbVie Reports Third-Quarter 2015 Financial Results (AbbVie Inc)
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Oct. 30, 2015/PRNewswire / -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2015. 'We are pleased with our...
View ArticleStudy: New Drug Combo May Cure Hepatitis C in Even the Sickest Patients...
(Source: Baylor Health Care System) Local researcher who participated in national hepatitis C drug study available to comment on results published today in New England Journal of Medicine 11/17/2015 -...
View ArticleJanssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with...
(Source: Johnson & Johnson) c5053730-3d54-465c-81d1-a0a6a3d74237.pdf November 16, 2015 Janssen Presents New Data Assessing OLYSIO® (Simeprevir) in Combination with Sofosbuvir in Genotype 4 Infected...
View ArticleU.S. FDA Approves New Indications for Harvoni®, Gilead’s Once-Daily Single...
(Source: Gilead Sciences Inc) – Label Expanded to Include Patients with Genotypes 4, 5 and 6 and Patients Co-Infected with HIV – – Use of Harvoni in Combination with Ribavirin for 12 Weeks Can be...
View ArticleGilead Submits New Drug Application to U.S. Food and Drug Administration for...
(Source: Gilead Sciences Inc) -- If Approved, Combination Would Be First All-Oral, Pan-Genotypic Single-Tablet Regimen for Chronic HCV Infection -- -- Filing is Company’s Third in Three Years for a New...
View ArticleHepatitis C Treatment Made Simple (Rush University Medical Center)
(Source: Rush University Medical Center) By Maggie Van Dyke The prognosis for people with hepatitis C has improved dramatically in the last few years, thanks to the introduction of direct-acting...
View ArticleMerck Announces Presentation of Phase 3 Results of Investigational...
(Source: Merck Canada Inc) 873e2286-eea9-4711-96a6-d4be85d53f3a.pdf News Release Media Contacts: Annick Robinson Investor Contacts: Justin Holko (438) 837-2550 (908) 740-1879 Merck Announces...
View ArticleGlobal aye for ayurveda treatment of liver cancer
MALAPPURAM: Research in liver cancer treatment by a government ayurveda doctor at Perinthalmanna here has won global recognition. The scientific expert committee of European Academy of Ayurveda has...
View ArticleBiotech Stock Roundup: Clovis Plunges, Label Expansion for Gilead's Harvoni
With earnings season winding down, regulatory and pipeline updates from the biotech sector are back in focus. Clovis Oncology’s CLVS shares plunged 70% as the company is possibly facing a delay in...
View ArticleAbbVie's Leadership and Innovation in Immunology Showcased at the American...
NORTH CHICAGO, Ill., Nov. 3, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that data on HUMIRA® (adalimumab), investigational medicines and the overall...
View ArticleIntercept Presents New PBC Data at AASLD 2015
Research Demonstrates Scope of Unmet Need in PBC New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term Risk of Liver Transplant and...
View ArticleMedicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by...
View ArticleBurman's Specialty Pharmacy - a Diplomat Company - Collaborate in Landmark...
FLINT, Mich., Nov. 23, 2015 /PRNewswire/ -- Burman's Specialty Pharmacy, a Diplomat company (NYSE: DPLO), released a landmark study with Penn Medicine to find differences in medication coverage for the...
View ArticleMedicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by...
View ArticleJUXTAPID(TM) (lomitapide) Capsules Available on the Régie de l'Assurance...
TORONTO, Nov. 20, 2015 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for...
View ArticleAbbVie's Commitment to Oncology Demonstrated at the 57th American Society of...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 5, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a leading biopharmaceutical company, will present data from clinical trials evaluating the company's oncology...
View ArticleAbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA...
NORTH CHICAGO, Ill., Nov. 13, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food...
View ArticleAbbVie Submits IMBRUVICA® (ibrutinib) Phase III Combination Data to U.S. FDA...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Nov. 13, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that it submitted a supplemental New Drug Application...
View ArticleIntercept Presents New PBC Data at AASLD 2015
Research Demonstrates Scope of Unmet Need in PBC New Analysis of Phase 3 POISE Study Uses Risk Algorithm to Examine Potential of OCA to Lower Patients' Long-Term Risk of Liver Transplant and...
View ArticleMedicaid Denies Nearly Half Of Requests For Hepatitis C Drugs: Study
People with hepatitis C who sought prescriptions for highly effective but pricey new drugs were significantly more likely to get turned down if they had Medicaid coverage than if they were insured by...
View Article